Natixis Raises Holdings in Kenvue Inc. (NYSE:KVUE)

Natixis increased its position in shares of Kenvue Inc. (NYSE:KVUE) by 29.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 315,489 shares of the company’s stock after buying an additional 71,545 shares during the period. Natixis’ holdings in Kenvue were worth $6,736,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in KVUE. Norges Bank purchased a new stake in shares of Kenvue during the 4th quarter worth $521,348,000. Franklin Resources Inc. grew its position in shares of Kenvue by 61.5% in the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company’s stock worth $912,059,000 after buying an additional 16,269,721 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Kenvue by 12.3% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company’s stock worth $2,085,070,000 after acquiring an additional 10,682,003 shares in the last quarter. Boston Partners raised its stake in shares of Kenvue by 36.9% during the 4th quarter. Boston Partners now owns 23,595,963 shares of the company’s stock worth $503,145,000 after acquiring an additional 6,366,097 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Kenvue in the fourth quarter valued at approximately $98,926,000. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Up 3.0 %

NYSE:KVUE opened at $23.42 on Monday. The firm has a market capitalization of $44.93 billion, a P/E ratio of 44.19, a PEG ratio of 2.62 and a beta of 1.02. The company’s fifty day moving average price is $22.91 and its 200-day moving average price is $22.41. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th will be given a $0.205 dividend. The ex-dividend date is Wednesday, May 14th. This represents a $0.82 annualized dividend and a yield of 3.50%. Kenvue’s dividend payout ratio is presently 154.72%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on KVUE shares. Canaccord Genuity Group upped their price target on Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. Redburn Atlantic assumed coverage on Kenvue in a research note on Thursday, April 10th. They issued a “neutral” rating and a $23.50 price target for the company. Citigroup boosted their price target on Kenvue from $21.00 to $22.00 and gave the stock a “neutral” rating in a research note on Monday, April 14th. Royal Bank of Canada restated a “sector perform” rating and set a $24.00 price objective on shares of Kenvue in a report on Monday, February 3rd. Finally, Barclays lowered their target price on shares of Kenvue from $23.00 to $22.00 and set an “equal weight” rating for the company in a research note on Monday, April 14th. Eight equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, Kenvue presently has an average rating of “Hold” and an average target price of $24.42.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.